Salute e Benessere
New report from Access to Medicine Foundation shows what pharma companies can do to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance
New report from the Access to Medicine Foundation tracks five such projects across the pipelines of GSK, F2G, Innoviva, Venatorx (gepotidacin , olorofim, zoliflodacin and cefepime-taniborbactam, respectively) and Pfizer's recently approved aztreonam-avibactam (Emblaveo®). Collectively, these projects could save at least 160,000 lives annually by providing much-needed medicines to treat drug-resistant gonorrhoea, urinary tract infections, intra-abdominal infections, respiratory infections, and invasive fungal infections. While these diseases affect a wide range of patients globally, women and children- especially those living in low-and middle-income countries (LMICs)- are disproportionately affected.
–
Findings reveal that companies are employing diverse range of strategies within their access and stewardship plans but structured advance planning has not yet become standard. Encouragingly, four of the five companies in scope, GSK, Pfizer, Innoviva, and Venatorx, are conducting or initiating clinical trials that directly target children, signalling progress in closing the gap between adult and paediatric access. Commitments for registration were identified in five LMICs: China , India , Mexico , South Africa , and Thailand . However, for 108 of 113 LMICs in scope, where people also face high burdens of the diseases targeted by these projects, it is currently unclear whether any of them will be made available upon initial approval.
The report identifies opportunities and recommendations for companies in focus and outlines actionable steps for global stakeholders in antimicrobial R&D to promote widespread adoption of advance access and stewardship planning.
As global health stakeholders prepare for 2024 UN General Assembly's High-level Meeting on AMR, this report comes at a crucial moment, emphasising the urgent gaps that need attention. Read the report here.
View original content:https://www.prnewswire.co.uk/news-releases/new-report-from-access-to-medicine-foundation-shows-what-pharma-companies-can-do-to-ensure-the-few-promising-antimicrobials-in-development-reach-patients-on-the-frontlines-of-drug-resistance-302148886.html